Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Research » 4th World Theranostics Congress Wrap Up

4th World Theranostics Congress Wrap Up

  • December 21, 2016
Thanks to an internationally commended Scientific Program facilitated by Prof Michael Hofman (Peter Mac), Prof Rod Hicks (Peter Mac) and Prof Richard Baum (Germany), the conference welcomed close to 400 delegates from 35 countries.

With a focus on advancements in treatment of Neuroendocrine (NET) cancer on day one and Prostate cancer on day two, the speaker presentations included:

Refining and Defining NET Targets
Chairs: Prof Frank Roesch, Prof Irina Velikyan

– Integrating cancer genomics with imaging
Dr Ben Lawrence, Auckland City Hospital
– Production of Ga-68 radiotracers under GMP and regulatory aspects – A German perspective
Dr Oliver Neels, German Cancer Research Centre (DKFZ) Heidelberg
– Optimised production of 64Cu-SARTATE for a phase 1 clinical trial
Charmaine Jeffery, Clarity Pharmaceuticals
– Influence of the radiopharmaceutical affinity and peptide content on the pharmacokinetics: (68Ga)Ga-DOTATOC and (68Ga)Ga-DOTATATE
Irina Velikyan, Uppsala University Hospital

Optimising Peptide Receptor Radionuclide Therapy (PRRT)
Chairs: Prof Harvey Turner, Dr Grace Kong

-Two Decades of THERANOSTICS in Neuroendocrine Tumors – Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)
Dr Harshad R Kulkarni on behalf of Prof Richard Baum, THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka
– NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-Dotatate: Efficacy, Safety, QoL Results and Subgroup Analysis
Prof Jonathan Strosberg, Moffitt Cancer Center
-Clinical Perspective: The “difficult development situation”: how to approach and overcome challenges from a regulatory perspective
Hans-Georg Eichler, European Medicines Agency 
-The Cruel Wait for PRRT
Paul Stephenson, The Unicorn Foundation

For the full program please click here

To watch all the presentations from day 1 – Focus on Neuroendocrine Tumors please click here

The feedback from the attendees was incredibly positive and special thanks to Charlotte Rhiane for her incredible performance at the Conference dinner. Charlotte is a friend of the Unicorn Foundation and her personal touch telling her story about her dad and his battle with NET Cancer was so appreciated by everyone present.

Thanks to the organising committee for their hard work and ASN Events for their professionalism in bringing the conference together.

If you missed a speaker or would like to watch the presentation again we will have all the videos available on our You Tube channel soon. Will send out a notification when available.  The 5th World Theranostics Congress will be held in South Korea in early 2018 and we wish the hosts a successful meeting.

Lastly thank you also to the major sponsors for their support:

Platinum Sponsor

Gold Sponsor

 

 Silver Sponsors

       

 Bronze Sponsor

 

 Speaker Sponsors

             

 

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

December 14, 2022

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

December 14, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousCommNETS Update from our NET Nurse Kate Wakelin
NextUF $1 million dollar research fundNext

Related Posts

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Read full report

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative